½ðɳjs93252¼¯ÍÅ-¹úÍâ¿ÆÑ§¼ÒÑз¢³æ²ÝËØÐÞÊÎÎïÌáÉý¿¹°©»îÐÔ
2026-03-09 02:09:07
ÍâÑó¿ÆÑ§¼ÒÑз¢³æ²ÝËØÈóÉ«Îï½úÉý¿¹°©»îÐÔ
ÈÕÆÚ£º2021-10-29 À´Àú£º±¾Õ¾ ¹©¸å£ºÖÐÒ½ÓëÖÐÒ©´¦ ×÷ÕߣºÖÎÀíÔ± ÖÖ±ð£º×ÔÁ¦×«Ð´
ϲÂíÀÑŵØÓòÌØ²úµÄ¶¬³æÏIJÝÒ»Ö±ÓÚÖÐÒ½Ò©Öб»ÓÃÔÚÒ½Öΰ©Ö¢¼°ÆäËûÑ×Ö¢ÐÔ¼²²¡£¬Æä»îÐÔÉí·ÖÊÇ3'-ÍÑÑõÏÙÜÕ£¨3'-dA£©£¬ÓÖÃû³æ²ÝËØ£¬ÊÇÒ»ÖÖ×ÔÈ»ºËÜÕ½üËÆÎï¡£ÒòΪ3'-dAÓÚѪҺÖÐÇáÒ×±»ÂÖ»ØÃ¸ÏÙÜÕÍѰ±Ã¸£¨ADA£©¿ìËÙË®½â¡¢Ï¸°ûÉãÈë²»Á¼ÒÔºÍÒÀ¿¿ÏÙÜÕ¼¤Ã¸£¨ADK£©¼¤»î£¬ÊÇÒÔÖ»ÓÐÉÙÁ¿µÄÒ©Îï±»ÔËË͵½Ö×ÁöÖС£ ½üÈÕ£¬Å£½òÄêҹѧÓëÉúÎïÖÆÒ©¹«Ë¾NuCanaµÄÑо¿ÍŶӻ¥ÖúÓÚÎÅÃû°©Ö¢Ñо¿Ñ§ÊõÆÚ¿¯¡¶Clinical Cancer Research¡·ÉÏ·¢±íÁËÌâΪ£ºThe novel nucleoside analogue ProTide NUC-7738 overcomes cancerresistance mechanisms in vi½ðɳjs93252¼¯ÍÅ-tro and in a first-in-human Phase 1 clinical trialµÄÑо¿ÂÛÎÄ¡£ Ñо¿Ö°Ô±¿ª·¢³öÁËÒ»ÖÖÐÂÐÍ¿¹°©Ò©Î¡ªNUC-7738¡£NUC-7738Ô´×ÔϲÂíÀÑŵØÓòµÄ¶¬³æÏIJÝÖÐÌáÈ¡µÄ³æ²ÝËØ£¬¾»¯Ñ§ÈóÉ«ºó£¬¿ÉÒÔ½µ·þÒªº¦µÄÄÍÒ©»úÖÆ²¢ÓÚ°©Ï¸°ûÄÚÔÐÓý·¢Éú¸ß³Ì¶ÈµÄ»îÐÔ¿¹°©´úлÎÆäЧÀÍÊdzæ²ÝËØµÄ40±¶¡£½ñ³¯ÕýÓÚ¾ÙÐÐ1ÆÚÁÙ´²ÊµÑ飬»¼Õß¶ÔÓÚNUC-7738µÄÄÍÊÜÐÔÓÅÁ¼£¬²¢ÏÔʾ³ö½ÏºÃµÄ¿¹°©»îÐÔ¼£Ïó¡£Ñо¿ÍŶӽ«½øÒ»²½¿ªÕ¹2ÆÚÁÙ´²ÊµÑé¡£ ÂÛÎÄÁ´½Ó£ºhttps://clincancerres.aacrjournals.org/content/early/2021/10/27/1078-0432.CCR-21-1652 ×¢£º´ËÑо¿½á¹ûÕª×ÔClinicalCancer Research£¬ÎÄÕÂÄÚÈݲ»´ú±í±¾ÍøÕ¾²»Ñŵ㼰̬¶È£¬½ö¹©²Î¿¼¡£-½ðɳjs93252¼¯ÍÅ-

¸ü¶à²âÊÔÊý¾Ý¾´ÇëÆÚ´ý……
.png)
.jpg)